摘要
目的 探讨黄芪注射液辅助治疗卵巢癌的疗效及对患者生活质量、炎症因子、T淋巴细胞的影响.方法 选取2014年9月至2016年8月卵巢癌患者66例,按照随机数字表法分为观察组和对照组,两组各33例.对照组采用紫杉醇联合顺铂(TP)方案治疗,观察组在对照组基础上加用黄芪注射液,治疗3个周期后,比较两组患者的治疗效果、生活质量、炎症因子、T淋巴细胞的变化情况.结果 观察组总有效率(ORR)和疾病控制率(DCR)均明显高于对照组(P<0.05);治疗后观察组生活质量评分(KPS)较治疗前显著提高(P<0.01),且明显高于对照组(P<0.05);治疗后两组血清TGF-β1、TGF-β2、IL-10水平与治疗前比均显著降低(P<0.01),且观察组显著低于对照组(P<0.01);观察组CD3+、CD4+、CD4+/CD8+水平与治疗前比较均有所提高(P<0.05),且观察组明显高于对照组(P<0.05).结论 黄芪注射液辅助治疗可以显著提高临床疗效,明显改善患者生活质量,降低炎症反应,改善患者免疫功能.
Objective To investigate the effect of astragalus injection adjuvant therapy on the therapeutic effect,quality of life,inflammatory factors and T lymphocyte in patients with ovarian cancer.Methods 66 patients with ovarian cancer were selected from Sep.2014 to Aug.2016 in our hospital,these patients were divided into observation group(33 cases)and control group(33 cases)according to the random number table method.The control group was treated with paclitaxel combined with cisplatin(TP).The observation group was treated with astragalus injection on the basis of the control group.After treatment for 3 cycles,the therapeutic effect,quality of life,inflammatory factors and T lymphocyte of the two groups were compared.Results The total effective rate(ORR)and disease control rate(DCR)in the observation group were significantly higher than those in the control group(P<0.05).After treatment,the quality of life score of the observation group was significantly higher than that before treatment(P<0.01),which was significantly higher than the control group.The levels of serum TGF-β1,TGF-β2 and IL-10 in the two groups were significantly lower than those before treatment(P<0.01),and the observation group was significantly lower than the control group(P<0.01).The levels of CD3+,CD4+,CD4+/CD8+in the observation group were significantly higher than those those before treatment(P<0.05),and the observation group was significantly higher than the control group(P<0.05).Conclusion Astragalus injection adjuvant therapy can significantly improve clinical efficacy,significantly improve the quality of life of patients,reduce the inflammatory response,improve immune function in patients.
出处
《浙江临床医学》
2019年第5期638-639,共2页
Zhejiang Clinical Medical Journal
基金
浙江省医学会科研资金项目(2017zyc-A99).
关键词
卵巢癌
黄芪注射液
炎症因子
T淋巴细胞
Ovarian cancer
Astragalus injection
Inflammatory factors
T lymphocyte